HIV DNA vaccine - CytRx

Drug Profile

HIV DNA vaccine - CytRx

Alternative Names: DP-6001

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Advanced BioScience Laboratories; University of Massachusetts Medical School
  • Developer Advanced BioScience Laboratories
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention) in USA (Parenteral)
  • 31 Jul 2006 Final results from a phase I study have been added to the adverse events and Viral Infections immunogenicity sections
  • 08 Sep 2005 Clinical data from a media release have been added to the adverse events and Viral infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top